Vanoglipel

Vanoglipel
Clinical data
Other namesDA-1241; DA1241
Drug classGPR119 agonist
Identifiers
  • 3-[4-[3-[1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-5-propan-2-yl-1,2,4-oxadiazole
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC25H31F2N5O2
Molar mass471.553 g·mol−1
3D model (JSmol)
  • CCC1=CN=C(N=C1)N1CCC(CCCOC2=CC(F)=C(C3=NOC(=N3)C(C)C)C(F)=C2)CC1
  • InChI=1S/C25H31F2N5O2/c1-4-17-14-28-25(29-15-17)32-9-7-18(8-10-32)6-5-11-33-19-12-20(26)22(21(27)13-19)23-30-24(16(2)3)34-31-23/h12-16,18H,4-11H2,1-3H3
  • Key:XQSZLXRXPGLHLH-UHFFFAOYSA-N

Vanoglipel (INNTooltip International Nonproprietary Name), also known by its developmental code name DA-1241, is an experimental GPR119 receptor agonist developed by the South Korean company Dong-A ST for non-alcoholic steatohepatitis and type 2 diabetes. As of August 2026, it is in phase 2 clinical trials for non-alcoholic steatohepatitis and phase 1 trials for type 2 diabetes.

See also